Resibufogenin protects against atherosclerosis in ApoE^-/- mice through blocking NLRP3 inflammasome assembly.

ABSTRACT:

Introduction

Atherosclerosis (AS), a major cause of cardiovascular diseases, is characterized by lipid accumulation and chronic inflammation within arterial walls. Traditional treatments, such as statins, are often ineffective for many patients, highlighting the need for novel therapeutic strategies.

Objective

This study explores the potential of Resibufogenin (RBG) as an NLRP3 inflammasome inhibitor for treating AS in ApoE^-/- mice.

Methods

We performed experiments encompassing cellular studies, animal model assessments, molecular simulations, and binding assays to assess RBG's impact on the NLRP3 inflammasome, inflammatory cytokine release, and foam cell formation.

Results

RBG treatment alleviated AS in ApoE^-/- mice, evidenced by reduced

SUBMITTER: Xiaoyang C 

PROVIDER: S-EPMC12869210 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature